Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | SAT1 | P21673 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23810261 | 0.98 | SIGMAR1 (0.59) | SIGMAR1CYP1A2SAT1CYP2C19MEN1 | |
| SCHEMBL19508398 | 0.94 | CYP1A2 (0.58) | SIGMAR1CYP1A2SAT1CYP2C19MEN1 | |
| SCHEMBL8396180 | 0.94 | CYP1A2 (0.58) | SIGMAR1CYP1A2SAT1CYP2C19MEN1 | |
| SCHEMBL23675585 | 0.94 | CYP1A2 (0.58) | SIGMAR1CYP1A2SAT1CYP2C19MEN1 | |
| SCHEMBL23235475 | 0.88 | CYP1A2 (0.52) | SIGMAR1CYP1A2SAT1CYP2C19MEN1 | |
| SCHEMBL8392349 | 0.87 | SAT1 (0.52) | SIGMAR1CYP1A2SAT1CYP2C19MEN1 | |
| SCHEMBL23099440 | 0.87 | SAT1 (0.57) | SIGMAR1CYP1A2SAT1CYP2C19MEN1 | |
| SCHEMBL7937894 | 0.86 | CYP1A2 (0.65) | SIGMAR1CYP1A2SAT1TSHR | |
| SCHEMBL27435880 | 0.86 | SIGMAR1 (0.51) | SIGMAR1CYP1A2SAT1TSHR | |
| SCHEMBL1483921 | 0.85 | CYP1A2 (0.50) | SIGMAR1CYP1A2SAT1CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010042500-A2 | HEAT SHOCK PROTEIN 90 INHIBITORS, METHODS OF PREPARING SAME, AND METHODS FOR THEIR USE | EMORY UNIVERSITY (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-1851190-A4 | COMPOSITIONS AND METHODS FOR INHIBITING PAIN | UNIV FLORIDA (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1851190-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PAIN | University of Florida (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006078239-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PAIN | UNIVERSITY OF FLORIDA (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160905-A1 | Compositions and methods for inhibiting pain | UNIVERSITY OF FLORIDA | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160905-A1 | Compositions and methods for inhibiting pain | OPRM1, OPRL1, OPRK1 | SIGMAR1 4/4885CYP1A2 1444/4885SAT1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.